サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1730895

遺伝性トランスサイレチンアミロイドーシスの世界市場レポート 2025年

Hereditary Transthyretin Amyloidosis Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.83円
遺伝性トランスサイレチンアミロイドーシスの世界市場レポート 2025年
出版日: 2025年05月16日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

遺伝性トランスサイレチンアミロイドーシスの市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.4％で21億4,000万米ドルに成長すると予想されます。予測期間中の成長は、高齢者人口の増加、可処分所得の増加、遺伝性トランスサイレチンアミロイドーシスの罹患率の上昇、新薬開発の成長、遺伝子検査の進歩などの要因によるものと考えられます。予測期間における主な動向としては、先進治療薬の開発、診断技術の発展、医薬品開発の進展、効果的な治療法に対する需要の高まり、医療技術の進歩などが挙げられます。

高齢者人口の増加が遺伝性トランスサイレチンアミロイドーシス市場の成長を牽引すると予想されます。65歳以上の個人と定義されるこの人口層は、加齢に伴い専門的なヘルスケアを必要とすることが多くあります。この人口層の成長は、ヘルスケアと生活水準の進歩による平均寿命の伸びに後押しされています。遺伝性トランスサイレチンアミロイドーシス（hATTR）は特に高齢者に影響を与え、進行性の神経障害や心筋症を引き起こし、高齢者の罹患率を増加させます。人口問題研究所によると、米国の65歳以上の人口は2022年の5,800万人から2050年には8,200万人へと47％増加すると予測されています。この高齢者人口の増加が市場の拡大に寄与しています。

遺伝性トランスサイレチンアミロイドーシス市場の各社は、トランスサイレチン（TTR）タンパク質の産生を抑えるRNAi治療薬など、最先端の治療薬を開発しています。RNAi治療薬は、RNA干渉技術を用いて特定の遺伝子を沈黙させ、病気の原因となるタンパク質の産生を抑えます。例えば、2024年10月、Alnylam Pharmaceuticals, Inc.は、心筋症を伴うトランスサイレチンアミロイドーシスを治療するためのヴトリシラン（AMVUTTRA）の新薬追加申請を米国FDAに提出しました。このRNAi療法は、疾患進行の鍵となるTTRタンパク質を標的とします。ヴトリシランの皮下投与は、静脈内投与に代わる、より患者に優しい治療法であり、この重篤な疾患に罹患した患者にとって有望な選択肢と位置づけられます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の遺伝性トランスサイレチンアミロイドーシス市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
  • 最終用途産業の分析
  • 世界の遺伝性トランスサイレチンアミロイドーシス市場：成長率分析
  • 世界の遺伝性トランスサイレチンアミロイドーシス市場の実績：規模と成長、2019～2024年
  • 世界の遺伝性トランスサイレチンアミロイドーシス市場の予測：規模と成長、2024～2029年、2034年
  • 世界の遺伝性トランスサイレチンアミロイドーシス総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の遺伝性トランスサイレチンアミロイドーシス市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 経口
  • 皮下注射
  • その他
  • 世界の遺伝性トランスサイレチンアミロイドーシス市場：薬剤クラス別、実績と予測、2019～2024年、2024～2029年、2034年
  • RNAi剤（パティシラン）
  • 低分子干渉RNA（siRNA）（ヴトリシラン）
  • 世界の遺伝性トランスサイレチンアミロイドーシス市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院薬局
  • 小売薬局
  • 世界の遺伝性トランスサイレチンアミロイドーシス市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院
  • クリニック
  • その他
  • 世界の遺伝性トランスサイレチンアミロイドーシス市場：経口のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • タファミディス
  • ジフルニサル
  • 実験的経口療法
  • 世界の遺伝性トランスサイレチンアミロイドーシス市場：皮下注射のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • パティシラン
  • イノテルセン
  • ヴトリシラン
  • 世界の遺伝性トランスサイレチンアミロイドーシス市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 静脈内療法
  • 遺伝子サイレンシング療法
  • CRISPRベース治療法

第7章 地域別・国別分析

  • 世界の遺伝性トランスサイレチンアミロイドーシス市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界の遺伝性トランスサイレチンアミロイドーシス市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 遺伝性トランスサイレチンアミロイドーシス市場：競合情勢
  • 遺伝性トランスサイレチンアミロイドーシス市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
    • Novo Nordisk Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Regeneron Pharmaceuticals Inc.
  • Alexion Pharmaceuticals Inc.
  • Alnylam Pharmaceuticals Inc.
  • PTC Therapeutics Inc.
  • Ionis Pharmaceuticals Inc.
  • BridgeBio Pharma Inc.
  • Akcea Therapeutics
  • Prothena Corporation plc
  • Intellia Therapeutics Inc.
  • YoITech Therapeutics
  • Corino Therapeutics Inc.
  • Attralus Inc.
  • BSIM Therapeutics SA
  • Eidos Therapeutics
  • Autotac Bio Inc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 遺伝性トランスサイレチンアミロイドーシス市場2029：新たな機会を提供する国
  • 遺伝性トランスサイレチンアミロイドーシス市場2029：新たな機会を提供するセグメント
  • 遺伝性トランスサイレチンアミロイドーシス市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r34567

Hereditary transthyretin amyloidosis (hATTR) is a rare, inherited disorder caused by mutations in the TTR gene, leading to the misfolding and accumulation of transthyretin protein as amyloid deposits in various organs. This condition primarily impacts the nervous system, heart, and other tissues, resulting in progressive neuropathy and cardiomyopathy.

The main treatment types for hereditary transthyretin amyloidosis include oral administration, subcutaneous injection, and other methods. Oral treatments, such as tablets, capsules, or liquids, provide a convenient and patient-friendly option, improving accessibility and adherence. The drug classes used in treating hATTR amyloidosis include RNAi agents such as patisiran and small interfering RNAs (siRNAs) such as vutrisiran. These therapies are distributed through hospital pharmacies and retail pharmacies and are used in settings such as hospitals, clinics, and other healthcare facilities.

The hereditary transthyretin amyloidosis market research report is one of a series of new reports from The Business Research Company that provides hereditary transthyretin amyloidosis market statistics, including the hereditary transthyretin amyloidosis industry global market size, regional shares, competitors with the hereditary transthyretin amyloidosis market share, detailed hereditary transthyretin amyloidosis market segments, market trends, and opportunities, and any further data you may need to thrive in the hereditary transthyretin amyloidosis industry. This hereditary transthyretin amyloidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hereditary transthyretin amyloidosis market size has grown strongly in recent years. It will grow from $1.36 billion in 2024 to $1.50 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth during the historic period can be attributed to factors such as the rising incidence of hereditary transthyretin amyloidosis, increased research and development activities, a growing number of cardiac amyloidosis cases, heightened disease awareness, and improvements in healthcare infrastructure.

The hereditary transthyretin amyloidosis market size is expected to see strong growth in the next few years. It will grow to $2.14 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth during the forecast period can be attributed to factors such as the increasing geriatric population, rising disposable incomes, a higher incidence of hereditary transthyretin amyloidosis, growth in the development of new drugs, and advancements in genetic testing. Key trends in the forecast period include the development of advanced treatment products, improvements in diagnostic techniques, progress in drug development, rising demand for effective therapies, and advancements in medical technology.

The increasing geriatric population is expected to drive the growth of the hereditary transthyretin amyloidosis market. This population, defined as individuals aged 65 and older, often requires specialized healthcare due to the aging process. The growth in this demographic is fueled by rising life expectancy, thanks to advancements in healthcare and living standards. Hereditary transthyretin amyloidosis (hATTR) particularly affects the elderly, causing progressive neuropathy and cardiomyopathy, which increases morbidity in older individuals. According to the Population Reference Bureau, the U.S. population aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. This growing geriatric population is contributing to the market's expansion.

Companies in the hereditary transthyretin amyloidosis market are developing cutting-edge therapeutics such as RNAi therapeutics to reduce the production of the transthyretin (TTR) protein. RNAi therapeutics use RNA interference technology to silence specific genes and reduce the production of proteins that cause diseases. For example, in October 2024, Alnylam Pharmaceuticals, Inc. submitted a supplemental new drug application (sNDA) to the U.S. FDA for Vutrisiran (AMVUTTRA) to treat transthyretin amyloidosis with cardiomyopathy. This RNAi therapy targets the TTR protein, a key player in the disease's progression. Vutrisiran's subcutaneous administration offers a more patient-friendly alternative to intravenous treatments, positioning it as a promising option for those affected by this severe condition.

In July 2023, Ionis Pharmaceuticals, Inc. entered into a partnership with AstraZeneca plc to co-develop and market eplontersen for treating transthyretin amyloidosis (ATTR) in the U.S. This collaboration also aims to enhance global access to the therapy by leveraging AstraZeneca's broad commercial presence, particularly in Latin America and other international regions. AstraZeneca is a UK-based biopharmaceutical company specializing in the discovery, development, and commercialization of prescription medicines.

Major players in the hereditary transthyretin amyloidosis market are Pfizer Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novo Nordisk, Regeneron Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Akcea Therapeutics, Prothena Corporation plc, Intellia Therapeutics Inc., YoITech Therapeutics, Corino Therapeutics Inc., Attralus Inc., BSIM Therapeutics SA, Eidos Therapeutics, and Autotac Bio Inc.

North America was the largest region in the hereditary transthyretin amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hereditary transthyretin amyloidosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hereditary transthyretin amyloidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hereditary transthyretin amyloidosis market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, and genetic counseling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary transthyretin amyloidosis market also includes sales of genetic testing kits, imaging technologies, biomarkers, and assays. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hereditary Transthyretin Amyloidosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hereditary transthyretin amyloidosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hereditary transthyretin amyloidosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hereditary transthyretin amyloidosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Oral; Subcutaneous Injection; Other Types
  • 2) By Drug Class: RNAi Agents (Patisiran); Small Interfering RNAs (siRNAs) (Vutrisiran)
  • 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies
  • 4) By Application: Hospital; Clinic; Other Applications
  • Subsegments:
  • 1) By Oral: Tafamidis; Diflunisal; Experimental Oral Therapies
  • 2) By Subcutaneous Injection: Patisiran; Inotersen; Vutrisiran
  • 3) By Other Types: Intravenous Therapies; Gene Silencing Therapies; CRISPR-Based Therapies
  • Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Sanofi S.A.; AstraZeneca plc; Novo Nordisk
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hereditary Transthyretin Amyloidosis Market Characteristics

3. Hereditary Transthyretin Amyloidosis Market Trends And Strategies

4. Hereditary Transthyretin Amyloidosis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Hereditary Transthyretin Amyloidosis Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Hereditary Transthyretin Amyloidosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Hereditary Transthyretin Amyloidosis Market Growth Rate Analysis
  • 5.4. Global Hereditary Transthyretin Amyloidosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Hereditary Transthyretin Amyloidosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Hereditary Transthyretin Amyloidosis Total Addressable Market (TAM)

6. Hereditary Transthyretin Amyloidosis Market Segmentation

  • 6.1. Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Subcutaneous Injection
  • Other Types
  • 6.2. Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • RNAi Agents (Patisiran)
  • Small Interfering RNAs (siRNAs) (Vutrisiran)
  • 6.3. Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • 6.4. Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital
  • Clinic
  • Other Applications
  • 6.5. Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Tafamidis
  • Diflunisal
  • Experimental Oral Therapies
  • 6.6. Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Subcutaneous Injection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Patisiran
  • Inotersen
  • Vutrisiran
  • 6.7. Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Intravenous Therapies
  • Gene Silencing Therapies
  • CRISPR-Based Therapies

7. Hereditary Transthyretin Amyloidosis Market Regional And Country Analysis

  • 7.1. Global Hereditary Transthyretin Amyloidosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Hereditary Transthyretin Amyloidosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hereditary Transthyretin Amyloidosis Market

  • 8.1. Asia-Pacific Hereditary Transthyretin Amyloidosis Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hereditary Transthyretin Amyloidosis Market

  • 9.1. China Hereditary Transthyretin Amyloidosis Market Overview
  • 9.2. China Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hereditary Transthyretin Amyloidosis Market

  • 10.1. India Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hereditary Transthyretin Amyloidosis Market

  • 11.1. Japan Hereditary Transthyretin Amyloidosis Market Overview
  • 11.2. Japan Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hereditary Transthyretin Amyloidosis Market

  • 12.1. Australia Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hereditary Transthyretin Amyloidosis Market

  • 13.1. Indonesia Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hereditary Transthyretin Amyloidosis Market

  • 14.1. South Korea Hereditary Transthyretin Amyloidosis Market Overview
  • 14.2. South Korea Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hereditary Transthyretin Amyloidosis Market

  • 15.1. Western Europe Hereditary Transthyretin Amyloidosis Market Overview
  • 15.2. Western Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hereditary Transthyretin Amyloidosis Market

  • 16.1. UK Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hereditary Transthyretin Amyloidosis Market

  • 17.1. Germany Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hereditary Transthyretin Amyloidosis Market

  • 18.1. France Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hereditary Transthyretin Amyloidosis Market

  • 19.1. Italy Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hereditary Transthyretin Amyloidosis Market

  • 20.1. Spain Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hereditary Transthyretin Amyloidosis Market

  • 21.1. Eastern Europe Hereditary Transthyretin Amyloidosis Market Overview
  • 21.2. Eastern Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hereditary Transthyretin Amyloidosis Market

  • 22.1. Russia Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hereditary Transthyretin Amyloidosis Market

  • 23.1. North America Hereditary Transthyretin Amyloidosis Market Overview
  • 23.2. North America Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hereditary Transthyretin Amyloidosis Market

  • 24.1. USA Hereditary Transthyretin Amyloidosis Market Overview
  • 24.2. USA Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hereditary Transthyretin Amyloidosis Market

  • 25.1. Canada Hereditary Transthyretin Amyloidosis Market Overview
  • 25.2. Canada Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hereditary Transthyretin Amyloidosis Market

  • 26.1. South America Hereditary Transthyretin Amyloidosis Market Overview
  • 26.2. South America Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hereditary Transthyretin Amyloidosis Market

  • 27.1. Brazil Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hereditary Transthyretin Amyloidosis Market

  • 28.1. Middle East Hereditary Transthyretin Amyloidosis Market Overview
  • 28.2. Middle East Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hereditary Transthyretin Amyloidosis Market

  • 29.1. Africa Hereditary Transthyretin Amyloidosis Market Overview
  • 29.2. Africa Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hereditary Transthyretin Amyloidosis Market Competitive Landscape And Company Profiles

  • 30.1. Hereditary Transthyretin Amyloidosis Market Competitive Landscape
  • 30.2. Hereditary Transthyretin Amyloidosis Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Novo Nordisk Overview, Products and Services, Strategy and Financial Analysis

31. Hereditary Transthyretin Amyloidosis Market Other Major And Innovative Companies

  • 31.1. Regeneron Pharmaceuticals Inc.
  • 31.2. Alexion Pharmaceuticals Inc.
  • 31.3. Alnylam Pharmaceuticals Inc.
  • 31.4. PTC Therapeutics Inc.
  • 31.5. Ionis Pharmaceuticals Inc.
  • 31.6. BridgeBio Pharma Inc.
  • 31.7. Akcea Therapeutics
  • 31.8. Prothena Corporation plc
  • 31.9. Intellia Therapeutics Inc.
  • 31.10. YoITech Therapeutics
  • 31.11. Corino Therapeutics Inc.
  • 31.12. Attralus Inc.
  • 31.13. BSIM Therapeutics SA
  • 31.14. Eidos Therapeutics
  • 31.15. Autotac Bio Inc

32. Global Hereditary Transthyretin Amyloidosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hereditary Transthyretin Amyloidosis Market

34. Recent Developments In The Hereditary Transthyretin Amyloidosis Market

35. Hereditary Transthyretin Amyloidosis Market High Potential Countries, Segments and Strategies

  • 35.1 Hereditary Transthyretin Amyloidosis Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Hereditary Transthyretin Amyloidosis Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Hereditary Transthyretin Amyloidosis Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer